Gina Mauro | Authors

February 13, 2021

Patients with metastatic renal cell carcinoma and brain metastases showed significant intracranial and extracranial responses with cabozantinib use.

February 11, 2021

Avelumab plus best supportive care as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy.

January 30, 2021

Patients with KRAS G12C–mutated advanced non–small cell lung cancer show antitumor response and survival benefit with the KRAS G12C inhibitor sotorasib, formerly AMG 510.

January 28, 2021

A real-world study enlightens to the importance of NRG1 fusions in non–small cell lung cancer and provides possible steps forward.

January 20, 2021

Overall survival benefits were noted when ivosidenib tablets were used in previously treated patients with IDH1-mutant cholangiocarcinoma when compared against placebo, according to a phase 3 trial.

December 14, 2020

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

December 13, 2020

The GP2/GM-CSF combination demonstrated a 100% disease-free survival at 5 years for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

December 12, 2020

For women with heavily pretreated, postmenopausal advanced or metastatic estrogen receptor (ER)–positive breast cancer, amcenestrant prompted antitumor activity.

December 10, 2020

Impressive signals of efficacy, durable responses, overall survival rates, and a tolerable safety profile were all found for fam-trastuzumab deruxtecan-nxki to treat patients with HER2-positive metastatic breast cancer.

December 09, 2020

Treatment with oral paclitaxel, compared with the intravenous formulation, in combination with encequidar led to an estimated 26.5% reduction in the risk of death in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.